Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients.
Pistelli M, De Lisa M, Ballatore Z, Caramanti M, Pagliacci A, Battelli N, Ridolfi F, Santoni M, Maccaroni E, Bracci R, Santinelli A, Biscotti T, Berardi R, Cascinu S. Pistelli M, et al. Among authors: battelli n. BMC Cancer. 2015 Mar 28;15:195. doi: 10.1186/s12885-015-1204-2. BMC Cancer. 2015. PMID: 25884918 Free PMC article.
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO, Matsubara N, Park SH, Huddart RA, Burgess EF, Özgüroğlu M, Valderrama BP, Laguerre B, Basso U, Triantos S, Akapame S, Kean Y, Deprince K, Mukhopadhyay S, Loriot Y; THOR cohort 2 investigators. Siefker-Radtke AO, et al. Ann Oncol. 2024 Jan;35(1):107-117. doi: 10.1016/j.annonc.2023.10.003. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871702 Clinical Trial.
Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Cascinu S, Frontini L, Comella G, Barni S, Labianca R, Battelli N, Casaretti R, Zonato S, Pirovano M, Catalano G, Cellerino R. Cascinu S, et al. Among authors: battelli n. Br J Cancer. 1999 Feb;79(3-4):491-4. doi: 10.1038/sj.bjc.6690076. Br J Cancer. 1999. PMID: 10027318 Free PMC article. Clinical Trial.
[Paraneoplastic syndromes: a review].
Berardi R, Grilli G, Romagnoli E, Saladino T, Freddari F, Tamburrano T, Galizia E, Carbonari G, Mariani C, Braconi C, Pierantoni C, Battelli N, Scartozzi M, Cascinu S. Berardi R, et al. Among authors: battelli n. Clin Ter. 2005 Nov-Dec;156(6):281-8. Clin Ter. 2005. PMID: 16463565 Review. Italian.
Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
Battelli N, Massacesi C, Braconi C, Pilone A, Manzione L, Dinota A, Cobelli S, Scanni A, Sturba F, Giacomini G, Morale D, Giorgi F, Tummarello D, Cascinu S. Battelli N, et al. Am J Clin Oncol. 2006 Aug;29(4):380-4. doi: 10.1097/01.coc.0000221356.81769.52. Am J Clin Oncol. 2006. PMID: 16891866 Clinical Trial.
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer.
Guarneri V, Frassoldati A, Ficarra G, Puglisi F, Andreetta C, Michelotti A, Cresti N, Boni C, Bisagni G, Berardi R, Battelli N, Santoro A, Banna G, Bottini A, Di Blasio B, Maiorana A, Piacentini F, Giovannelli S, Jovic G, Conte P. Guarneri V, et al. Among authors: battelli n. Breast Cancer Res Treat. 2008 Jul;110(1):127-34. doi: 10.1007/s10549-007-9688-3. Epub 2007 Aug 9. Breast Cancer Res Treat. 2008. PMID: 17687648 Free article. Clinical Trial.
108 results